Friday, August 24, 2018 4:23:00 AM
My take on the smoking cessation drug is this:
1. Get patent
2. Offer a significant % of patent rights (future profits if approved by FDA or however companies structure such deals) to a bug pharma co in exchange for the big pharma paying for the clinical trials
This keeps us out of paying millions for trials that may prove this drug to be non effective. Most drugs that enter trials are never approved by FDA and not all FDA approved drugs are successful in the market
So if they are smart they do this. That way we can keep growing profits and shareholder value. And if the trials go bust we dont lose anything. If the trials and drug are approved and are a blockbuster drug we win big too on top of our CBD direct to consumer products.
Make sense? Thoughts???
1. Get patent
2. Offer a significant % of patent rights (future profits if approved by FDA or however companies structure such deals) to a bug pharma co in exchange for the big pharma paying for the clinical trials
This keeps us out of paying millions for trials that may prove this drug to be non effective. Most drugs that enter trials are never approved by FDA and not all FDA approved drugs are successful in the market
So if they are smart they do this. That way we can keep growing profits and shareholder value. And if the trials go bust we dont lose anything. If the trials and drug are approved and are a blockbuster drug we win big too on top of our CBD direct to consumer products.
Make sense? Thoughts???
Recent CVSI News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
